{"classes":[{"categories":[{"measurements":[{"comment":"Median OS was not reached due to more than 50% of participants still being alive.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper confidence interval (CI) is not estimable. The upper CI is not estimable when there are insufficient (or no) events past the time reported to calculate the upper CI limit. It is mathematically not possible to determine the upper limit in those cases.","groupId":"OG001","lowerLimit":"1.1","upperLimit":"NA","value":"28.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"OS is the time from treatment start date until date of death from any cause, date last known alive or last follow up. OS will be estimated for each of the two types of lymphoma individually using Kaplan-Meier curves with appropriate confidence intervals reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cohort 1: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (i.e., Gray-zone lymphoma or GZL)\n\nParticipants will be treated with pembrolizumab 200 mg (flat dose) intravenous (IV) every 3 weeks provided they have clinical benefit and no unacceptable toxicity; participants who achieve a complete response (CR) will have the option to stop after 1 year of therapy.","id":"OG000","title":"Cohort 1 Gray-Zone Lymphoma (GZL)"},{"description":"Cohort 2: Extra-nodal diffuse large B-cell lymphoma involving one or more of the specified extra-nodal sites (i.e., extra-nodal DLBCL)\n\nParticipants will be treated with pembrolizumab 200 mg (flat dose) intravenous (IV) every 3 weeks provided they have clinical benefit and no unacceptable toxicity; participants who achieve a complete response (CR) will have the option to stop after 1 year of therapy.","id":"OG001","title":"Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL)"}],"paramType":"MEDIAN","populationDescription":"9/10 participants are analyzed in the DLBCL cohort because 1 participant was not evaluable due to withdrawal of consent prior to treatment.","reportingStatus":"POSTED","timeFrame":"every 3-6 months, up to 2.5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}